Table 3 Associations of proinsulin-processing metabolites with RA features
From: Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients
Β-coefficient (95% CI) | ||||
|---|---|---|---|---|
Insulin and C-peptide (dependent variables) | ||||
log Insulin p M | P | log C-peptide | P | |
RA versus controls (β 95% CI for RA, 101, and controls, 99) | 0.39 (0.14-0.64) | 0.00 | 0.61 (0.32-0.91) | 0.00 |
GC-RA versus controls (β 95% CI for RA, 56, and controls, 99) | 0.14 (0.01-0.27) | 0.04 | 0.20 (0.02-0.38) | 0.03 |
GC+RA versus controls (β 95% CI for RA, 55, and controls, 99) | 0.15 (0.06-0.25) | 0.00 | 0.29 (0.17-0.40) | 0.00 |
RA patients features (β 95% CI for RA, 101) | ||||
Disease duration | -0.79 (-3.32-1.74) | 0.54 | -0.01 (-0.02-0.00) | 0.07 |
RF positivity | -10. 9 (-46.9-25.2) | 0.99 | 0.03 (-0.06-0.12) | 0.51 |
ESR | -0.50 (-1.49-0.50) | 0.33 | -0.00 (-0.01-0.00) | 0.12 |
CRP | -0.21 (-1.34-0.91) | 0.03 | 0.00 (-0.00-0.00) | 0.65 |
Current prednisone | 0.13 (-0.23-0.48) | 0.48 | 0.10 (0.01-0.18) | 0.02 |
Prednisone, mg/day/previous 3 months | -3.28 (-22.36-15.80) | 0.25 | -0.02 (-0.05-0.02) | 0.16 |
HAQ | 3.03 (-20.32-26.37) | 0.63 | -0.02 (-0.09-0.05) | 0.69 |
DAS28 | -0.21 (-10.89-10.49) | 0.67 | 0.00 (-0.03-0.03) | 0.99 |
Current nonbiologic DMARD | 23.58 (-63.53-110.68) | 0.79 | 0.05 (-0.13-0.23) | 0.61 |
logIntact proinsulin (dependent variable) | ||||
Intact proinsulin | p | Intact proinsulin/C-peptide ratio | p | |
RA versus controls (β 95% CI for RA, 101, and controls, 99) | 0.81 (0.13-1.46) | 0.02 | 0.55 (0.05-1.05) | 0.03 |
GC-RA versus controls (β 95% CI for RA, 56, and controls, 99) | 0.34 (0.05-0.62) | 0.02 | 1.65 (-0.06-3.35) | 0.06 |
GC+RA versus controls (β 95% CI for RA, 55, and controls, 99) | 0.24 (0.05-0.43) | 0.01 | 0.14 (-0.04-0.33) | 0.13 |
RA patients features (β 95% CI for RA, 101) | ||||
Disease duration | 0.03 (-0.46-0.51) | 0.83 | 0.13 (-0.45-0.71) | 0.96 |
RF positivity | 3.4 (0.25-6.51) | 0.11 | 3.45 (-0.34-7.25) | 0.15 |
ESR | -0.03 (-0.12-0.06) | 0.92 | 0.01 (-0.11-0.10) | 0.62 |
CRP | 0.02 (-0.07-0.12) | 0.50 | 0.03 (-0.08-0.14) | 0.47 |
Current prednisone | -0.07 (-0.73-0.59) | 0.83 | -1.40 (-5.30-2.50) | 0.48 |
Prednisone. mg/day/previous 3 months | -0.11 (-1.86-1.65) | 0.82 | -0.05 (-1.83-1.73) | 0.63 |
HAQ | 0.62 (-2.13-3.37) | 0.75 | 1.23 (-1.99-4.46) | 0.85 |
DAS28 | 0.49 (-0.74-1.72) | 0.65 | 0.39 (-1.03-1.82) | 0.68 |
Current nonbiologic DMARD | 2.93 (-7.52-13.34) | 0.91 | 3.40 (-7.45-14.26) | 0.96 |
logSplit proinsulin (dependent variable) | ||||
Split proinsulin | P | Split proinsulin/C-peptide ratio | P | |
RA versus controls (β 95% CI for RA, 101, and controls, 99) | 0.70 (0.38-1.02) | 0.00 | 0.57 (0.30-0.88) | 0.00 |
GC-RA versus controls (β 95% CI for RA, 56, and controls, 99) | 0.19 (0.00-0.36) | 0.04 | 0.16 (-0.02-0.34) | 0.08 |
GC+RA versus controls (β 95% CI for RA, 55, and controls, 99) | 0.33 (0.20-0.45) | 0.00 | 0.25 (0.12-0.38) | 0.00 |
RA patients features (β 95% CI for RA, 101) | ||||
Disease duration | -1.58 (-2.84-0.31) | 0.01 | -1.82 (-3.48-0.17) | 0.02 |
RF positivity | 2.83 (-8.33-13.98) | 0.60 | 5.11 (-8.54-18.76) | 0.67 |
ESR | 0.08 (-0.39-0.22) | 0.60 | -0.02 (-0.39-0.35) | 0.93 |
CRP | 0.16 (-0.18-0.51) | 0.42 | 0.20 (-0.23-0.62) | 0.33 |
Current prednisone | 0.57 (0.18-0.96) | 0.00 | 0.41 (0.05-0.76) | 0.03 |
Prednisone. mg/day/previous 3 months | -1.04 (-6.99-4.91) | 0.98 | -0.14 (-6.50-6.22) | 0.71 |
HAQ | -3.17 (-11.15-4.81) | 0.11 | -0.35 (-10.84-10.14) | 0.43 |
DAS28 | 1.11 (-2.89-5.11) | 0.82 | -1.79 (-3.01-6.67) | 0.67 |
Current nonbiologic DMARD | 15.28 (-15.93-46.49) | 0.83 | 15.43 (-17.36-48.23) | 0.73 |